混元迭代性能躍升 智能體應用成果凸顯

AI賦能主業穩健增長

香港2026年5月13日 /美通社/ -- 世界領先的互聯網科技公司——騰訊控股有限公司(港交所代碼:00700(港幣櫃台)及80700(人民幣櫃台)，「騰訊」或「本公司」)今天公佈截至二零二六年三月三十一日止第一季(「1Q2026」)未經審核綜合業績。

董事會主席兼首席執行官馬化騰表示:「二零二六年伊始，我們在新AI產品上取得了顯著突破，並持續以AI賦能核心業務增長。重組後的AI研發團隊重構了AI基礎設施，搭建了Hy3 preview模型，在同等參數規模的模型中性能領先，兼具實用性與性價比；自4月28日以來，其在OpenRouter的token消耗量排行榜上穩居前列。我們的效率AI智能體解決方案已初見成效，我們相信，WorkBuddy目前是中國使用最廣的效率AI智能體服務。同時，我們的核心業務在用戶粘性、收入及盈利上持續增長，既為AI投入提供了充裕的現金流支持，也為AI的落地應用奠定了豐富的場景基礎。」

1Q2026財務摘要

總收入:同比增長9%，毛利:同比增長11%，按非國際財務報告準則的經營盈利:同比增長9%

• 總收入為人民幣1,965億元，較二零二五年第一季(「同比」)增長9%。
• 毛利為人民幣1,113億元，同比增長11%。
• 按非國際財務報告準則，撇除若干一次性及/或非現金項目的影響，以體現核心業務的業績:

• • 經營盈利為人民幣756億元，同比增長9%; 經營利潤率為38.5%，較去年持平。
  • 若剔除新AI產品^[1]，經營盈利為人民幣844億元，同比增長17%; 若剔除新AI產品，經營利潤率由去年的39.9%提升至43.0%。
  • 盈利為人民幣698億元，同比增長11%。
  • 本公司權益持有人應佔盈利為人民幣679億元，同比增長11%。
  • 每股基本盈利為人民幣7.517元，每股攤薄盈利為人民幣7.364元。

• 按國際財務報告準則:

• • 經營盈利為人民幣674億元，同比增長17%; 經營利潤率由去年的32.0%提升至34.3%。
  • 盈利為人民幣594億元，同比增長19%。
  • 本公司權益持有人應佔盈利為人民幣581億元，同比增長21%。
  • 每股基本盈利為人民幣6.431元，每股攤薄盈利為人民幣6.302元。

• 資本開支為人民幣319億元，同比增加16%。
• 總現金為人民幣 5,337 億元，同比增長12%。自由現金流為人民幣567億元，同比增長20%。現金淨額為人民幣1,469億元，同比增長63%。
• 於2026年3月31日，我們於上市投資公司(不包括附屬公司)權益^[2]的公允價值為人民幣5,471億元，對比2025年12月31日的公允價值為人民幣6,727億元。於2026年3月31日，我們於非上市投資公司(不包括附屬公司)權益的賬面價值為人民幣3,651億元，對比2025年12月31日的賬面價值為人民幣3,631億元。
• 1Q2026，本公司於香港聯交所以約76億港元的總代價回購約1,265萬股股份。

1Q2026管理層討論及分析

增值服務1Q2026收入同比增長4%至人民幣961億元。本土市場遊戲收入為人民幣454億元，同比增長6%，收入增速滯後於本土市場遊戲流水增速，因2026年春節假期晚於2025年，導致更多收入遞延至本季之後確認。本土市場遊戲流水同比增長十幾個百分點，因受《王者榮耀》、《和平精英》等現有長青遊戲，以及《三角洲行動》(近期已躋身長青遊戲之列) 、《無畏契約：源能行動》等近期發佈遊戲的推動。國際市場遊戲收入為人民幣188億元，同比增長13%(按固定匯率計算為14%)，增長主要由《部落衝突：皇室戰爭》、《鳴潮》及《無畏契約》個人電腦端所帶動。社交網絡收入同比下降2%至人民幣319億元，因2026年春節假期晚於2025年，令1Q2026確認的本土市場手機遊戲應用道具銷售收入較1Q2025減少。

營銷服務1Q2026收入為人民幣382億元，同比增速由4Q2025的17%提升至本季的20%。我們升級了AI驅動的廣告推薦模型，擴展了微信生態內的閉環營銷能力，從而改善了廣告效果，提升了廣告單價。大多數主要行業的廣告主投放本季度均有增長，其中互聯網服務、電商和遊戲行業的增長尤其顯著。

金融科技及企業服務1Q2026的收入同比增長9%至人民幣599億元。金融科技服務收入增長主要由商業支付及理財服務收入的增長驅動。企業服務收入同比增長20%，其中得益於國內與海外市場需求提升(包括AI相關服務)以及更有利的定價環境共同推動了雲服務收入增長，及微信小店交易額上升而帶動商家技術服務費收入增長。

經營數據

1Q2026業務回顧及展望

• 我們多款長青遊戲^[4]在本季流水創下新高，包括《王者榮耀》、《和平精英》和《三角洲行動》，新遊戲《洛克王國：世界》也大受歡迎。
• 我們的智能投放產品矩陣騰訊營銷AIM+賦能了廣告主營銷服務投放金額的約30%，並在小遊戲、短劇和微信小店廣告主中獲得了廣泛應用。
• 我們擴大了視頻號內容推薦模型參數規模並優化了模型算法，向用戶推送更相關的內容。視頻號總用戶使用時長同比增長超過20%。
• 我們為微信小店品牌商家提供了激勵措施，並向資深買家推出了優惠券分享功能，微信小店交易額維持快速的同比增長。
• 商業支付金額同比增速較4Q2025提升，受益於交易筆數持續增長，以及零售與餐飲服務等品類的筆均交易金額上升。
• 騰訊雲效率AI智能體解決方案實現了快速的增長與健康的留存率。其中，以日活躍賬戶數計，WorkBuddy已成為中國最受歡迎的效率AI智能體服務。
• 四月我們發佈了基於重構後的AI基礎設施上搭建的Hy3 preview大語言模型。我們相信Hy3 preview在推理、智能體和代碼的能力上，為同等參數規模的模型中表現最佳的。自4月28日以來，以token消耗量計，其已成為OpenRouter上最廣受使用的模型。

有關更詳細的披露，請瀏覽https://www.tencent.com/zh-hk/investors.html或通過微信公眾號(微信號:TencentGlobal)关注我们。

關於騰訊

騰訊以技術豐富互聯網用戶的生活。

通過通信及社交服務微信和QQ，促進用戶互相連接，並助其連接數字內容、網上及線下服務。通過定向營銷服務，助力廣告主觸達數以億計的中國消費者。通過金融科技及企業服務，促進合作夥伴業務增長，助力實現數字化升級。

騰訊大力投資於人才隊伍和推動科技創新，積極參與互聯網行業協同發展。騰訊於1998年在中國深圳成立，騰訊2004年於香港聯合交易所上市。

投資者查詢:[email protected]
媒體查詢:[email protected]

非國際財務報告準則財務計量

為補充根據國際財務報告準則編制的本集團(「本公司及其附屬公司」)綜合業績，若干額外的非國際財務報告準則財務計量(經營盈利、經營利潤率、期內盈利、本公司權益持有人應佔盈利、每股基本盈利及每股攤薄盈利)已於本公佈內呈列。此等未經審核非國際財務報告準則財務計量應被視為根據國際財務報告準則編制的本集團財務業績的補充而非替代計量。此外，此等非國際財務報告準則財務計量的定義可能與其他公司所用的類似詞彙有所不同。

本公司的管理層相信，非國際財務報告準則財務計量藉排除若干非現金項目及投資相關交易的若干影響為投資者評估本集團核心業務的業績提供有用的補充資料。此外，非國際財務報告準則調整包括本集團主要聯營公司的相關非國際財務報告準則調整，此乃基於相關主要聯營公司可獲得的已公佈財務資料或本公司管理層根據所獲得的資料、若干預測、假設及前提所作出的估計。

重要注意事項

本新聞稿載有前瞻性陳述，涉及本集團的業務展望、財務表現估計、預測業務計劃及增長策略。該等前瞻性陳述是根據本集團現有的資料，亦按本新聞稿刊發之時的展望為基準，在本新聞稿內載列。該等前瞻性陳述是根據若干預測、假設及前提，當中有些涉及主觀因素或不受我們控制。該等前瞻性陳述或會證明為不正確及可能不會在將來實現。該等前瞻性陳述涉及許多風險及不明朗因素。鑑於風險及不明朗因素，本新聞稿內所載列的前瞻性陳述不應視為董事會或本公司聲明該等計劃及目標將會實現，故投資者不應過於倚賴該等陳述。

Significant Progress in Hy Capabilities and Productivity AI Agents 

Utilising AI to Grow Existing Core Businesses

HONG KONG, May 13, 2026 /PRNewswire/ -- Tencent Holdings Limited (HKEX: 00700 (HKD Counter) and 80700 (RMB Counter), "Tencent" or "the Company"), a world-leading Internet and technology company in China, today announced the unaudited consolidated results for the quarter ended 31 March 2026 ("1Q2026").

Mr. Ma Huateng, Chairman and CEO of Tencent, said, "We started 2026 by making significant initial progress on our new AI products, as well as continuing to utilise AI to grow our existing core businesses. The Hy3 preview model, built by our revamped team of AI researchers on re-architected AI infrastructure, is a leader in its parameter size class, delivering practical utility and cost efficiency, and has been top ranked in OpenRouter token measurements since April 28. Our productivity AI agent solutions have attained early traction, and we believe that our WorkBuddy is currently the most widely used productivity AI agent service in China. Our core businesses continued to grow their engagement, revenue and profit, providing the cash flow to fund our AI investments, as well as use cases for future AI deployment."

1Q2026 Financial Highlights

Revenues: +9% YoY, gross profit: +11% YoY, non-IFRS operating profit: +9% YoY

• Total revenues were RMB196.5 billion, up 9% over the first quarter of 2025 ("YoY").
• Gross profit was RMB111.3 billion, up 11% YoY.
• On a non-IFRS basis, which is intended to reflect core earnings by excluding certain one-time and/or non-cash items:
  • Operating profit was RMB75.6 billion, up 9% YoY. Operating margin was largely stable at 38.5%.
  • Operating profit excluding new AI products^[1] was RMB 84.4 billion, increased by 17% YoY. Operating margin excluding new AI products increased to 43.0% from 39.9% last year.
  • Net profit was RMB 69.8 billion, up 11% YoY.
  • Net profit attributable to equity holders of the Company was RMB67.9 billion, up 11% YoY.
  • Basic earnings per share were RMB7.517. Diluted earnings per share were RMB7.364.
• On an IFRS basis:
  • Operating profit was RMB67.4 billion, up 17% YoY. Operating margin increased to 34.3% from 32.0% last year.
  • Net profit was RMB59.4 billion, up 19% YoY.
  • Net profit attributable to equity holders of the Company was RMB58.1 billion, up 21% YoY.
  • Basic earnings per share were RMB6.431. Diluted earnings per share were RMB6.302.

• Capital expenditure was RMB31.9 billion, up 16% YoY.
• Total cash was RMB533.7 billion, up 12%. Free cash flow was RMB56.7 billion, up 20% YoY. Net cash position totalled RMB146.9 billion, up 63%.
• The fair value of our shareholdings^[2] inlisted investee companies (excluding subsidiaries) totalled RMB547.1 billion as at 31 March 2026, compared with RMB672.7 billion as at 31 December 2025. The carrying book value of our shareholdings inunlisted investee companies (excluding subsidiaries) was RMB365.1 billion as at 31 March 2026, compared with RMB363.1 billion as at 31 December 2025.
• During 1Q2026, the Company repurchased approximately 12.7 million shares on the Hong Kong Stock Exchange for an aggregate consideration of approximately HKD7.6 billion.

1Q2026 Management Discussion and Analysis

Revenues from VAS increased by 4% year-on-year to RMB96.1 billion for 1Q2026. Domestic Games revenues were RMB45.4 billion, up 6% YoY, with revenue growth lagging Domestic Games gross receipts growth, as the later timing of the Spring Festival period in 2026 versus 2025 shifted a portion of revenue recognition out of the current quarter. Domestic Games gross receipts grew at a teens percentage rate YoY, driven by existing evergreen games including Honour of Kings and Peacekeeper Elite, as well as more recent game releases including Delta Force, which has recently qualified for the definition of an evergreen game, and VALORANT Mobile. International Games revenues were RMB18.8 billion, up 13% YoY (14% on a constant-currency basis), primarily driven by higher revenues from Clash Royale, Wuthering Waves and VALORANT PC. Social Networks revenues decreased by 2% YoY to RMB31.9 billion, as the later timing of the Spring Festival period resulted in less revenue recognition for domestic app-based game item sales during 1Q2026 versus 1Q2025.

Revenues from Marketing Services were RMB38.2 billion for 1Q2026, up 20% YoY, improving from 17% YoY growth in 4Q2025. We upgraded our AI-driven ad recommendation model and expanded closed-loop marketing capabilities within the Weixin ecosystem, which improved ad performance and pricing. Advertising spending grew across most major industry categories during the quarter, with notable growth from Internet services, eCommerce and games categories.

Revenues from FinTech and Business Services increased by 9% YoY to RMB59.9 billion for 1Q2026. FinTech Services revenue growth was mainly due to higher revenues from commercial payment and wealth management services. Business Services revenues rose by 20% YoY, with growth led by increased cloud services revenues supported by higher demand across domestic and international markets, including demand for AI-related services, and a more favorable pricing environment, as well as higher eCommerce technology service fees arising from growth in Mini Shops GMV.

Operating Metrics

1Q2026 Business Review and Outlook

• Several of our evergreen games^[4] achieved life-time highs in quarterly gross receipts, including Honour of Kings, Peacekeeper Elite and Delta Force, while new game Roco Kingdom: World achieved substantial popularity.
• Our automated campaign management solution AIM+ powered approximately 30% of our total marketing services spending from advertisers, gaining notable traction among mini game, mini drama and mini shop advertisers.
• We scaled up the number of parameters and enhanced the algorithms for Video Accounts' content recommendation model, enabling delivery of more relevant content to users. Total time spent on Video Accounts grew over 20% year-on-year.
• Mini Shops sustained a rapid year-on-year growth rate in GMV as we offered incentives for brand merchants and introduced coupon sharing features for frequent buyers.
• Commercial payment volume grew at a faster year-on-year rate than 4Q2025, benefitting from ongoing increase in number of transactions and higher value per transaction in categories such as retail and dining services.
• Tencent Cloud's productivity AI agent solutions achieved rapid growth and healthy retention rates. Among which, WorkBuddy was the most popular productivity AI agent service in China, measured by DAU.
• In April, we launched the Hy3 preview large language model, building upon a revamped AI infrastructure. We believe the Hy3 preview model is currently best in class among similar-size models in terms of reasoning, agentic and coding capabilities, and has become the most used model on OpenRouter since April 28, measured by token usage.

For other detailed disclosure, please refer to our website https://www.tencent.com/en-us/investors.html, or follow us via Weixin Official Account (Weixin ID: TencentGlobal)

About Tencent

Tencent uses technology to enrich the lives of Internet users.

Our communication and social services, Weixin and QQ, connect users with each other and with digital content and services, both online and offline, making their lives more convenient. Our targeted marketing services helps advertisers reach out to hundreds of millions of consumers in China. Our FinTech and business services support partners' business growth and assist their digital upgrade.

Tencent invests heavily in talent and technological innovation, actively promoting the development of the Internet industry. Tencent was founded in Shenzhen, China, in 1998. Tencent has been listed on the Main Board of the Stock Exchange of Hong Kong since 2004.

Investor contact: [email protected]
Media contact: [email protected]

Non-IFRS Financial Measures

To supplement the consolidated results of the Group ("the Company and its subsidiaries") prepared in accordance with IFRS, certain additional non-IFRS financial measures (in terms of operating profit, operating margin, profit for the period, profit attributable to equity holders of the Company, basic EPS and diluted EPS) have been presented in this press release. These unaudited non-IFRS financial measures should be considered in addition to, not as a substitute for, measures of the Group's financial performance prepared in accordance with IFRS. In addition, these non-IFRS financial measures may be defined differently from similar terms used by other companies.

The Company's management believes that the non-IFRS financial measures provide investors with useful supplementary information to assess the performance of the Group's core operations by excluding certain non-cash items and certain impact of investment-related transactions. In addition, non-IFRS adjustments include relevant non-IFRS adjustments for the Group's major associates based on available published financials of the relevant major associates, or estimates made by the Company's management based on available information, certain expectations, assumptions and premises.

Forward-Looking Statements

This press release contains forward-looking statements relating to the business outlook, estimates of financial performance, forecast business plans and growth strategies of the Group. These forward-looking statements are based on information currently available to the Group and are stated herein on the basis of the outlook at the time of this press release. They are based on certain expectations, assumptions and premises, some of which are subjective or beyond our control. These forward-looking statements may prove to be incorrect and may not be realised in the future. Underlying these forward-looking statements are a lot of risks and uncertainties. In light of the risks and uncertainties, the inclusion of forward-looking statements in this press release should not be regarded as representations by the Board or the Company that the plans and objectives will be achieved, and investors should not place undue reliance on such statements.

CONDENSED CONSOLIDATED INCOME STATEMENT 

RMB in millions, unless specified

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME 

RMB in millions, unless specified

OTHER FINANCIAL INFORMATION 

RMB in millions, unless specified

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

RMB in millions, unless specified

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION (continued)

RMB in millions, unless specified

RECONCILIATIONS OF THE GROUP'S NON-IFRS FINANCIAL MEASURES TO THE NEAREST MEASURES PREPARED IN ACCORDANCE WITH IFRS

SK Hynix (000660.KS) CEO Kwak Noh-Jung will meet with Microsoft Corporation (MSFT.US) Co-founder Bill Gates and CEO Satya Nadella in the US, Korean media reported, citing sources.

The event is expected to further deepen the strategic partnership between Microsoft and SK Hynix, particularly in HBM supply.

Microsoft is a major customer of SK Hynix's DRAM and NAND flash products.
~

AASTOCKS Financial News
Website: www.aastocks.com

Driving the development of Macao as World Centre of Tourism and Leisure through integration, innovation, and inclusion

MACAO, May 13, 2026 /PRNewswire/ -- At Tuesday's opening ceremony of G2E Asia 2026, the annual trade show and conference for the Asian gaming industry, Grant Chum, chief executive officer and executive director of Sands China Ltd., delivered the keynote address to 200 industry leaders and tourism stakeholders from across the region at The Venetian^® Macao. The keynote shed light on insights to Macao's integrated tourism development and pathways to its citywide diversification.

Themed "Evolving Together: Advancing Macao's Diversification Through Integration, Innovation, and Inclusion," the keynote speech outlined how Sands China's visionary integration, transformative innovation, and inclusive growth have collectively shaped a blueprint for Macao's sustainable development.

Such a forward-looking blueprint traces back to the far-sighted vision of Sheldon G. Adelson, the late founder of Las Vegas Sands Corp. Under his leadership, the group's first property in Macao, Sands^® Macao, was launched in 2004; it was followed by the 2007 launch of The Venetian^® Macao, the city's first large-scale integrated resort that merges retail, entertainment, hospitality, and MICE facilities. Ever since, Sands China has laid the foundation for the Cotai Strip, ushering in a new era for Macao's tourism industry.

To support Macao's economic diversification, Sands China has continuously invested in a holistic focus on hospitality, MICE, entertainment, and retail. Its 14,000-seat Venetian Arena, constantly staging large-scale concerts and performances by international superstars, has played a key role in positioning Macao more prominently on the global stage.

The company also operates over 1.6 million square feet of MICE facilities, instrumental in drawing world-class MICE events and a large flow of business visitors to Macao, extending visitors' stay, and further strengthening Macao's status as a leading business tourism destination in Asia. In addition, Sands China owns the city's largest retail offering, comprising nearly 780 world-renowned duty-free retail outlets, providing strong support for the development of Macao's retail sector.

As the pioneer of the integrated resort model in Macao, Sands China has remained steadfast in fostering the city's economic diversification for over 20 years and continues to hold strong confidence in its future development. With the leadership of the central and the Macao SAR governments, Macao's long-term political stability under the "One Country, Two Systems" framework has positioned the city as a safe, resilient operating environment for long-term investment, sustained development, and high-quality growth. Macao further benefits from strong organic demand – driven by its proximity to a population of nearly 90 million in the Greater Bay Area and its connectivity to key global markets. Together with tourism infrastructure developed by Sands China and industry peers over years, the synergy that has formed enables Macao to continuously attract diverse groups of tourists and effectively capture visitor demand.

Furthermore, Macao's supply advantage in having an unmatched critical mass of high-quality integrated resorts, together with government-backed infrastructure such as the Hong Kong–Zhuhai–Macao Bridge, have further enabled the scale and efficiency of Macao's tourism ecosystem and sustained its competitiveness.

Looking ahead, Chum underscored the growing importance of the "Event Economy" as a key driver of the next phase of Macao's diversification journey, with purposeful programming playing an increasingly strategic role in attracting international visitors and facilitating further economic diversification. The future focus for Sands China is on the curation of globally significant events to maximize impact and long-term value. Crucially, such events generate a broader spillover effect across the city's economy, benefitting a wider scope of industries.  

Flagship entertainment and sports events are also identified as powerful brand amplifiers for the city. In particular, The NBA China Games in October 2025 marked a significant milestone. It generated approximately 3 billion online impressions on social media platforms across the Chinese mainland and significantly enhanced Macao's visibility within global sports and entertainment networks. Around the event, Sands China curated around 100 extended activities and initiatives, including NBA House, the Impact Week community event, fan engagement, and Macao's first NBA flagship store, ensuring the impact extended beyond the arena into the wider community.

The significance of sustainable diversification lies not only in tourism benefits, but also in creating meaningful and lasting contributions to the local community. By extending the synergy from large-scale events, Sands China has endeavoured to promote community care, bolstering volunteer service, fostering the development of Macao's arts and culture, empowering SMEs, and advancing community revitalization – ensuring tourism growth drives broader participation and shared benefits across society.

Sands China reaffirms its unwavering confidence in Macao's future and pledges to continue investing in high-quality non-gaming projects, working closely with the government, industry and Macao community to further facilitate the city's development as a World Centre of Tourism and Leisure.

About Sands China Ltd.

Sands China Ltd. (Sands China or the Company) is incorporated in the Cayman Islands with limited liability and is listed on The Stock Exchange of Hong Kong Limited (HKEx: 1928). Sands China is the largest operator of integrated resorts in Macao. The Company's integrated resorts on the Cotai Strip comprise The Venetian^® Macao, The Plaza^® Macao, The Parisian^® Macao and The Londoner^® Macao. The Company also owns and operates Sands^® Macao on the Macao peninsula. The Company's portfolio features a diversified mix of leisure and business attractions and transportation operations, including large meeting and convention facilities; a wide range of restaurants; shopping malls; world-class entertainment at The Venetian Arena, The Londoner Arena, The Venetian Theatre, The Parisian Theatre, The Londoner Theatre and Sands Theatre; and a high-speed Cotai Water Jet ferry service between Hong Kong and Macao. The Company's Cotai Strip portfolio has the goal of contributing to Macao's transformation into a world centre of tourism and leisure. Sands China is a subsidiary of global resort developer Las Vegas Sands Corp. (NYSE: LVS).

For more information, please visit www.sandschina.com.

Media contacts:
Corporate Communications, Sands China Ltd.
Mabel Wu
Tel: +853 8118 2268
Email: [email protected]

Jesse Chiang
Tel: +853 8118 2054
Email: [email protected]

美國馬里蘭州羅克維爾市和中國蘇州2026年5月13日 /美通社/ -- 致力於在腫瘤等領域開發創新藥物的領先的生物醫藥企業——亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）宣佈，公司核心產品的17項臨床進展將在2026年歐洲血液學協會（EHA）年會上公佈，涉及公司原創1類新藥、中國首個上市的第三代BCR-ABL抑制劑奧雷巴替尼（商品名：耐立克^®；研發代號：HQP1351），以及公司原創1類新藥、中國首個上市的國產原創Bcl-2選擇性抑制劑利沙托克拉（商品名：利生妥^®；研發代號：APG-2575）。其中包括8項壁報展示。該會議將於6月11日至14日在瑞典斯德哥爾摩舉行。

作為全球血液領域極具權威性與影響力的頂尖學術盛會，EHA年會匯聚全球血液學領域專業人士，分享全球最前沿的研究進展和突破性臨床數據。

入選壁報展示的主要摘要信息包括：

UPDATED EFFICACY AND SAFETY OF OLVEREMBATINIB (HQP1351) AS SECOND-LINE THERAPY IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)

奧雷巴替尼（HQP1351）作為慢性期慢性髓細胞白血病（CP-CML）二線治療的最新療效與安全性

• 摘要編號：PS1733
• 展示時間：
  6月13日 週六 晚上18:45-19:45（中歐夏令時）
  6月14日 週日 凌晨00:45 - 01:45（北京時間）
• 第一作者：黎緯明教授，華中科技大學同濟醫學院附屬協和醫院血液科

EFFICACY OF OLVEREMBATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) WITH PRIOR RESISTANCE TO PONATINIB OR ASCIMINIB AND ASXL1 MUTATIONS

奧雷巴替尼治療既往對泊那替尼或阿思尼布耐藥且攜帶ASXL1基因突變的慢性期慢性髓細胞白血病（CP-CML）患者的療效

• 摘要編號：PS1727
• 展示時間：
  6月13日 週六 晚上18:45-19:45（中歐夏令時）
  6月14日 週日 凌晨00:45 - 01:45（北京時間）
• 第一作者：Elias Jabbour, MD，美國德克薩斯大學MD安德森癌症中心白血病科

UPDATED RESULTS OF POLARIS-1 (PART 1), A GLOBAL REGISTRATIONAL PHASE 3 STUDY: OLVEREMBATINIB COMBINED WITH LOW-INTENSITY CHEMOTHERAPY IN NEWLY DIAGNOSED PH+ ALL

POLARIS-1研究（第一部分）最新結果：奧雷巴替尼聯合低強度化療治療新診斷費城染色體陽性急性淋巴細胞白血病（Ph+ ALL）的全球註冊III期臨床研究

• 摘要編號：PS1479
• 展示時間
  6月13日 週六 晚上18:45-19:45（中歐夏令時
  6月14日 週日 凌晨00:45 - 01:45（北京時間）
• 第一作者：陳蘇寧教授，蘇州大學附屬第一醫院

CORRELATION OF BASELINE CHARACTERISTICS WITH PROGNOSIS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) TREATED WITH LISAFTOCLAX (APG-2575) IN A PIVOTAL PHASE 2 STUDY

一項關鍵II期臨床研究中利沙托克拉（APG-2575）治療的慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者基線特徵與預後的相關性

• 摘要編號：PS1713
• 展示時間：
  6月13日 週六 晚上18:45-19:45（中歐夏令時）
  6月14日 週日 凌晨00:45 - 01:45（北京時間）
• 第一作者：周可樹教授，河南省腫瘤醫院

SAFETY AND PRELIMINARY EFFICACY OF OLVEREMBATINIB (HQP1351) COMBINED WITH LISAFTOCLAX (APG-2575) IN PEDIATRIC PATIENTS WITH RELAPSED/REFRACTORY (R/R PH+ ALL): RESULTS OF A PHASE 1B STUDY

一項1B期臨床研究結果：奧雷巴替尼（HQP1351）聯合利沙托克拉（APG-2575）治療復發/難治性（R/R）費城染色體陽性急性淋巴細胞白血病（Ph+ ALL）兒童患者的安全性與初步療效

• 摘要編號：PS1473
• 展示時間：
  6月13日 週六 晚上18:45-19:45（中歐夏令時）
  6月14日 週日 凌晨00:45 - 01:45（北京時間）
• 第一作者：章婧嫽 中國醫學科學院血液病醫院（中國醫學科學院血液學研究所）

全部摘要信息(含壁報展示和在線發佈)請查詢EHA官網。

關於亞盛醫藥

亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）是一家綜合性的全球生物醫藥企業，致力於研發、生產和商業化創新藥，以解決腫瘤領域全球患者尚未滿足的臨床需求。公司已建立豐富的創新藥產品管線，包括抑制Bcl-2和 MDM2-p53 等細胞凋亡通路關鍵蛋白的抑制劑、新一代針對癌症治療中出現的激酶突變體的抑制劑以及蛋白降解劑。

公司核心品種耐立克^®是中國首個獲批上市的第三代BCR-ABL抑制劑，已獲批用於治療伴有T315I突變的慢性髓細胞白血病慢性期（CML-CP）和加速期（CML-AP）患者，以及對一代和二代TKI耐藥和/或不耐受的CML-CP成年患者。該藥物所有獲批適應症均已被納入中國國家醫保藥品目錄（NRDL）。目前，亞盛醫藥正在開展耐立克^®三項全球註冊III期臨床研究，分別為：獲美國FDA和歐洲EMA許可的評估耐立克^®治療新診斷費城染色體陽性急性淋巴細胞白血病（Ph+ ALL）患者POLARIS-1研究；獲美國FDA和歐洲EMA許可的評估耐立克^®治療經治CML-CP成年患者的POLARIS-2研究；評估耐立克^®治療SDH-缺陷型GIST患者的POLARIS-3研究。

公司另一重磅品種利生妥^®是一款用於治療多種血液系統惡性腫瘤的新型Bcl-2抑制劑。利生妥^®已獲中國國家藥品監督管理局（NMPA）批准，用於治療既往至少接受過一種包括布魯頓酪氨酸激酶（BTK）抑制劑在內的系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者。目前，亞盛醫藥正在開展利生妥^®四項全球註冊III期臨床研究，分別為：獲美國FDA和歐洲MEA許可的評估利生妥^®聯合BTK抑制劑治療既往接受BTK抑制劑治療超過12個月且應答不佳的CLL/SLL患者的GLORA研究；評估利生妥^®一線治療初治CLL/SLL患者的GLORA-2研究；評估利生妥^®一線治療新診斷老年或不耐受的AML患者的GLORA-3研究；以及獲美國FDA和歐洲EMA許可的評估利生妥^®一線治療新診斷中高危MDS患者的GLORA-4研究。

憑借強大的研發能力，亞盛醫藥已在全球範圍內進行知識產權佈局，並與武田、阿斯利康、默沙東、輝瑞、信達等眾多領先的生物製藥公司達成全球合作，同時與丹娜法伯癌症研究院、梅奧醫學中心、美國國家癌症研究所和密西根大學等學術機構建立研發合作關係。如需瞭解更多信息，請訪問 https://ascentage.com/

前瞻性聲明

本新聞稿包含根據美國《1995年私人證券訴訟改革法案》，以及經修訂的《1933年證券法》第27A條和《1934年證券交易法》第21E條所界定的前瞻性陳述。除歷史事實陳述外，本新聞稿中的所有內容均可能構成前瞻性陳述，包括亞盛醫藥對未來事件、經營成果或財務狀況所發表的意見、預期、信念、計劃、目標、假設或預測。

這些前瞻性陳述受到諸多風險和不確定性的影響，具體內容已在亞盛醫藥向美國證券交易委員會（SEC）提交的文件中詳細說明，包括2025年1月21日提交的經修訂的F-1表格註冊說明書和2025年4月16日提交的20-F表格中的「風險因素」和「關於前瞻性聲明的警示聲明」章節、2019年10月16日提交的首次發行上市招股書中的「前瞻性聲明」、「風險因素」章節，以及我們不時向SEC或HKEX提交的其他文件。這些因素可能導致實際業績、運營水平、經營成果或成就與前瞻性陳述中明示或暗示的信息存在重大差異。本前瞻性聲明中的陳述不構成公司管理層的利潤預測。

因此，該等前瞻性陳述不應被視為對未來事件的預測。本新聞稿中的前瞻性陳述僅基於亞盛醫藥當前對未來發展及其潛在影響的預期和判斷，且僅代表截至陳述發表之日的觀點。無論出現新信息、未來事件或其他情況，亞盛醫藥均無義務更新或修訂任何前瞻性陳述。

NVIDIA Corporation (NVDA.US) CEO Jensen Huang boarded Air Force One in Alaska, joining more than a dozen US corporate CEOs to participate in US President Donald Trump's visit to China this week, foreign media reported, citing people with the knowledge of the matter.

Huang did not appear on a preliminary list of senior attendees previously provided by the White House. A US official said last month that NVIDIA's high-performance H200 chips have not yet been sold to China owing to difficulties in obtaining approval from the Chinese government. The White House has not responded to the matter.
~

AASTOCKS Financial News
Website: www.aastocks.com

CHENGDU, China, May 12, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approving the Investigational New Drug (IND) application for PD-1 x VEGF bispecific antibody SKB118 (also known as CR-001) for the treatment of advanced solid tumors.

In December 2025, Kelun-Biotech and Crescent Biopharma ("Crescent") entered into a strategic collaboration for SKB118/CR-001. Under the collaboration, Crescent granted Kelun-Biotech exclusive rights to research, develop, manufacture and commercialize SKB118/CR-001 in Greater China (including Mainland China, Hong Kong, Macau, and Taiwan). In January 2026, Crescent announced the regulatory clearance of the IND application for SKB118/CR-001 by the U.S. Food and Drug Administration (FDA) to initiate its global ASCEND Phase I/II clinical trial (NCT07335497) for the treatment of locally advanced or metastatic solid tumors. The trial is ongoing and expected to initially enroll up to 290 patients.

Dr. Michael Ge, CEO of Kelun-Biotech, stated: "We are pleased to see the approval of the IND application for SKB118 in China, which marks the simultaneous advancement of clinical development in China and globally. Since entering into the collaboration with Crescent, we have worked closely and leveraged complementary advantages with each other to efficiently drive the R&D of the collaborative product candidates. Based on our ADC+IO strategies, we will actively explore the potential of combining SKB118 with our proprietary ADC assets to unlock the synergistic value of our portfolio and expand more treatment possibilities for cancer patients."

About SKB118 (also known as CR-001)

SKB118 is a tetravalent bispecific antibody being developed for the treatment of solid tumors that combines two complementary, validated mechanisms in oncology via a blockade of PD-1 and VEGF. PD-1 checkpoint inhibition is aimed at restoring T cells' ability to recognize and destroy tumor cells, and blocking VEGF is intended to reduce blood supply to tumor cells and to inhibit tumor growth. In preclinical studies, SKB118 demonstrated cooperative pharmacology with increased binding to PD-1 and signal blockade in the presence of VEGF as well as robust anti-tumor activity. SKB118's anti-VEGF activity may also normalize the vasculature at the tumor site, which has the potential to improve the localization and effectiveness of combination therapies, such as in combination with antibody-drug conjugates (ADCs).

About Kelun-Biotech

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/

SAN FRANCISCO and SUZHOU, China, May 13, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that it will present multiple clinical and preclinical data from mazdutide and its next‑generation obesity and metabolic pipeline at the 2026 American Diabetes Association's^® (ADA) Scientific Sessions, to be held in New Orleans, U.S. from June 5–8, 2026.

Dr. Lei Qian, Chief R&D Officer (General Biomedicine) of Innovent, stated, "At this year's ADA Scientific Sessions, we are pleased to present a series of new data in obesity and metabolic diseases, which is an important step in establishing Innovent as an emerging leader and innovator in this field. The multiple oral presentations of mazdutide, across adults with type 2 diabetes and obesity, adults with obesity and adolescents with obesity, further highlight its differentiated profile as a GCG/GLP‑1 dual receptor agonist in terms of weight loss, glycemic control and metabolic benefits. In addition, the data on IBI3032(oral daily GLP-1 small molecule), IBI3042(oral weekly GLP-1 small molecule), IBI3040(amylin) and IBI3046(INHBE siRNA) represent key milestones of our next‑generation obesity pipeline with global potential, which are designed to address unmet needs around tolerability, muscle preservation, dosing convenience, durability of weight loss and management of obesity‑related comorbidities."

Abstracts Summary at ADA 2026:

Mazdutide Oral Presentations

1. Title: Mazdutide versus Semaglutide in Chinese Adults with Type 2 Diabetes and Obesity (DREAMS-3): A Randomized, Open-Label Phase 3b Clinical Trial
Abstract No.: 1226-OR
Time: 8:15 AM – 8:30 AM, Sunday, June 7, 2026 (Central Time, U.S.)
Presenter: Professor Linong Ji, Peking University People's Hospital

2. Title: Efficacy and Safety of Mazdutide 9 mg in Chinese Adults with Obesity: Results from the Phase 3 GLORY-2 Clinical Trial
Abstract No.: 1225-OR
Time: 8:00 AM – 8:15 AM, Sunday, June 7, 2026 (Central Time, U.S.)
Presenter: Dr. Leili Gao, Peking University People's Hospital

3. Title: Safety, Tolerability and Pharmacokinetics of Once-Weekly Mazdutide in Chinese Adolescents with Obesity: A Phase 1b Clinical Trial
Abstract No.: 1133-OR
Time: 5:30 PM – 5:45 PM, Friday, June 5, 2026 (Central Time, U.S.)
Presenter: Professor Chunxiu Gong, Beijing Children's Hospital, Capital Medical University

These three studies together cover type 2 diabetes with obesity, adult with obesity and adolescent obesity, and will comprehensively demonstrate the clinical value of mazdutide in weight management, glycemic control and metabolic improvement, further strengthening its differentiated positioning as a next‑generation GCG/GLP‑1 dual receptor agonist in the obesity and metabolic disease areas.

Mazdutide Poster Presentations

4. Title: Mazdutide, a GCGR/GLP-1R Dual Agonist, Alleviates MASH and Liver Fibrosis through Hepatocytes–Hepatic Stellate Cells Cross Talk*
Abstract Number: 2505-P
Date & Time: Sunday, June 7, 2026, 12:30-1:30 PM (Central Time, USA)
Presenter: Dr. Lingfeng Zhang, China Pharmaceutical University

5. Title: Dual GLP-1R/GCGR Activation Reprograms Systemic and Hepatic Metabolism to Ameliorate MAFLD*
Abstract Number: 1686-P
Date & Time: Sunday, June 7, 2026, 12:30-1:30 PM (Central Time, USA)
Presenter: Dr. Danni Gao, Beijing Hospital

*Abstracts 2505-P & 1686-P are from investigator-initiated clinical trials (IIT).

Next-gen Innovative Pipeline Poster Presentations

1. Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032, a Novel Oral Nonpeptide GLP-1 Receptor Agonist: Single- and Multiple-Ascending Dose Studies in Chinese Adults
Abstract No.: 1690-P
Time: 12:30 PM – 1:30 PM, Sunday, June 7, 2026 (Central Time, U.S.)
Presenter: Dr. Huan Deng, Innovent Biologics

2. Title: IBI3032: An Orally Bioavailable Nonpeptidic GLP-1 Receptor Agonist Advancing Through Phase 1 Clinical Trials
Abstract No.: 1678-P
Time: 12:30 PM – 1:30 PM, Sunday, June 7, 2026 (Central Time, U.S.)
Presenter: Dr. Decheng Ren, Innovent Biologics

3. Title: IBI3040, a Novel Amylin Analog, Induces Superior Weight Loss in Preclinical Models
Abstract No.: 3077-LB
Time: 12:30 PM – 1:30 PM, Sunday, June 7, 2026 (Central Time, U.S.)
Presenter: Dr. Yuqiang Niu, Innovent Biologics

4. Title: IBI3042: A Novel Oral Once-Weekly Small-Molecule GLP-1 Receptor Agonist for Type 2 Diabetes and Obesity
Abstract No.: 2543-P
Time: 12:30 PM – 1:30 PM, Monday, June 8, 2026 (Central Time, U.S.)
Presenter: Dr. Decheng Ren, Innovent Biologics

5. Title: IBI3046, an INHBE siRNA, Enables High Quality and Long-Lasting Weight Control in Preclinical Study
Abstract No.: 2662-P
Time: 12:30 PM – 1:30 PM, Monday, June 8, 2026 (Central Time, U.S.)
Presenter: Dr. Xiguang Zhang, Innovent Biologics

Taken together, IBI3032 and IBI3042, as next‑generation oral daily and weekly GLP‑1 receptor agonists, along with IBI3040 (a novel amylin analog) and IBI3046 (an INHBE-targeting siRNA), form a layered and differentiated innovation portfolio for Innovent in the global obesity and metabolic comorbidity space. These programs are designed to address key global obesity challenges, including improving tolerability, reducing muscle loss, extending dosing intervals, maintaining durable weight loss, and comprehensively managing obesity‑related comorbidities.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 18 products in the market. It has 5 assets in Phase III or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

成都2026年5月13日 /美通社/ -- 四川科倫博泰生物醫藥股份有限公司(「科倫博泰」或「公司」，6990.HK)宣佈，已收到國家藥品監督管理局(NMPA)藥品審評中心(CDE)同意PD-1 x VEGF雙抗SKB118(亦稱CR-001)新藥臨床試驗(IND)申請的臨床試驗通知書，用於治療晚期實體瘤。

2025年12月，科倫博泰與Crescent Biopharma (「Crescent」)就SKB118/CR-001達成戰略合作。根據該合作協定，Crescent授予科倫博泰在大中華區(包括中國大陸、香港、澳門及臺灣)研究、開發、生產及商業化SKB118/CR-001的獨家權利。2026年1月，Crescent宣佈美國食品藥品監督管理局(FDA)已批准SKB118/CR-001的IND申請，以啟動其針對局部晚期或轉移性實體瘤的全球ASCEND I/II期臨床試驗(NCT07335497)，該研究正在進行中並初步計畫入組290例患者。

科倫博泰首席執行官葛均友博士表示：「很高興看到SKB118在中國的IND申請順利獲批，實現了中國與全球臨床開發的同步推進。自與Crescent達成合作以來，雙方通過緊密協作、優勢互補，高效推動了合作專案的研發。公司將基於ADC+IO策略積極探索SKB118與自身ADC資產的聯用潛力，以充分發揮產品管線的協同價值，為癌症患者拓展更多治療可能。」

關於SKB118（亦稱CR-001）

SKB118是一款四價雙特異性抗體，目前正開發用於治療實體瘤。其結合了腫瘤學中兩種互補且經過驗證的作用機制——PD-1和VEGF阻斷，其中對PD-1檢查點的抑制可恢復T細胞識別和摧毀腫瘤細胞的能力，而VEGF阻斷可減少對腫瘤細胞的血液供應並抑制腫瘤生長。在臨床前研究中，SKB118在VEGF存在的情況下顯示出提升PD-1的結合和信號阻斷能力的協同藥理作用，並具有強大的抗腫瘤活性。SKB118的抗VEGF活性還可能使腫瘤部位的血管正常化，有望提高聯合療法(例如與抗體偶聯藥物(ADC)聯用)在腫瘤局部的富集與療效。

關於科倫博泰

四川科倫博泰生物醫藥股份有限公司(簡稱「科倫博泰」，股票代碼：6990.HK)是科倫藥業控股子公司，專注于創新生物技術藥物及小分子藥物的研發、生產、商業化及國際合作。公司圍繞全球和中國未滿足的臨床需求，重點佈局腫瘤、自身免疫和代謝等重大疾病領域，建設國際化藥物研發與產業化平臺，致力於成為在創新藥物領域國際領先的企業。公司目前擁有30余個重點創新藥項目，其中4個項目8個適應症已獲批上市，1個專案處於NDA階段，10餘個專案正處於臨床階段。公司成功構建了享譽國際的專有ADC及新型偶聯藥物平臺OptiDC^TM，已有2個ADC項目5個適應症獲批上市，多個ADC或新型偶聯藥物產品處於臨床或臨床前研究階段。

GUANGZHOU, China, May 12, 2026 /PRNewswire/ -- TCL CSOT, a global leader in advanced display technologies and a subsidiary of TCL Technology, held a topping-out ceremony for its Gen 8.6 Inkjet-printed OLED (IJP OLED) production line in Guangzhou, China, known as the t8 project. With the completion of the main factory structure and the cleaning work, the world's first Gen 8.6 IJP OLED production line has entered its next critical phase of development.

Key Milestone Reached: Project Enters New Stage

As a strategic initiative, the t8 project drives TCL CSOT's next-gen display layout and IJP OLED industrial scaling. With a total investment of US$4.34 billion (RMB 29.5 billion)^[1] and a monthly capacity of 22,500 glass substrates, the project achieved remarkable efficiency. Following its groundbreaking on Nov. 30, 2025, the main structure was completed in just 151 days—setting an industry record for the fastest topping-out and epitomizing TCL CSOT's efficiency.

Dr. Weiran Cao, Chief of the IJP OLED Center at TCL CSOT, said, "Our early completion honors our team's dedication. As the world's first mass-production Gen 8.6 IJP OLED line, t8 secures our leadership in the next-gen display industry."

Following the topping-out, the project will enter the comprehensive stages of finish work, power-system installation, and core-equipment relocation.  

Deepening Technological Accumulation: A New Engine for Industrial Upgrading

With 13 years of R&D experience in IJP OLED technology, TCL CSOT has built a full end-to-end production system. The Wuhan G5.5 IJP OLED line in China, known as t12, achieved mass production and product delivery in November 2024, providing mature experience and optimized yields necessary to drive the t8 project forward efficiently.

As the world's first mass-production Gen 8.6 IJP OLED line, the t8 project utilizes inkjet-printing processes to precisely deposit organic light-emitting materials onto 2290×2620mm Gen 8.6 glass substrates via "on-demand deposition." Compared to traditional vacuum evaporation, IJP OLED offers superior material utilization, higher yields, and eco-friendly production. Targeting the high-end mid-size display market—including mobile, desktop, TV and automotive displays—this project bolsters premium supply and marks TCL CSOT's transition from pilot R&D to advanced manufacturing.

Looking ahead, with the completion and activation of the t8 project, TCL CSOT will gradually build an OLED product portfolio covering multiple sizes and scenarios. By leveraging cutting-edge technologies and premium products, TCL CSOT aims to deliver the ultimate display experience to global users.